FNY Managed Accounts LLC bought a new position in Vertex Pharmaceuticals Incorporated (NASDAQ:VRTX) during the third quarter, according to its most recent disclosure with the SEC. The firm bought 1,072 shares of the pharmaceutical company’s stock, valued at approximately $162,000.

Other institutional investors also recently made changes to their positions in the company. Smithfield Trust Co. bought a new position in Vertex Pharmaceuticals in the 3rd quarter worth $135,000. Northwestern Mutual Wealth Management Co. raised its holdings in Vertex Pharmaceuticals by 15.4% in the 2nd quarter. Northwestern Mutual Wealth Management Co. now owns 988 shares of the pharmaceutical company’s stock worth $127,000 after purchasing an additional 132 shares during the period. FNY Partners Fund LP raised its holdings in Vertex Pharmaceuticals by 900.0% in the 2nd quarter. FNY Partners Fund LP now owns 1,000 shares of the pharmaceutical company’s stock worth $128,000 after purchasing an additional 900 shares during the period. Fuller & Thaler Asset Management Inc. purchased a new stake in Vertex Pharmaceuticals in the 3rd quarter worth $198,000. Finally, Intact Investment Management Inc. purchased a new stake in Vertex Pharmaceuticals in the 3rd quarter worth $213,000. 92.42% of the stock is currently owned by institutional investors.

Vertex Pharmaceuticals Incorporated (NASDAQ VRTX) opened at $146.55 on Monday. The firm has a market capitalization of $37,062.93, a PE ratio of 244.25, a PEG ratio of 3.72 and a beta of 1.63. The company has a current ratio of 3.28, a quick ratio of 3.14 and a debt-to-equity ratio of 0.01. Vertex Pharmaceuticals Incorporated has a 12-month low of $71.46 and a 12-month high of $167.85.

Vertex Pharmaceuticals (NASDAQ:VRTX) last issued its quarterly earnings data on Wednesday, October 25th. The pharmaceutical company reported $0.53 earnings per share for the quarter, beating the Zacks’ consensus estimate of $0.04 by $0.49. The firm had revenue of $578.20 million during the quarter, compared to analyst estimates of $522.07 million. Vertex Pharmaceuticals had a return on equity of 9.23% and a net margin of 8.53%. The business’s quarterly revenue was up 39.7% compared to the same quarter last year. During the same quarter last year, the business posted $0.16 earnings per share. sell-side analysts forecast that Vertex Pharmaceuticals Incorporated will post 0.76 EPS for the current year.

In other news, CMO Jeffrey Chodakewitz sold 3,437 shares of the firm’s stock in a transaction dated Monday, October 2nd. The stock was sold at an average price of $151.64, for a total transaction of $521,186.68. The sale was disclosed in a document filed with the Securities & Exchange Commission, which is accessible through this hyperlink. Also, COO Ian F. Smith sold 75,000 shares of the firm’s stock in a transaction dated Tuesday, October 31st. The shares were sold at an average price of $145.06, for a total value of $10,879,500.00. Following the transaction, the chief operating officer now owns 114,188 shares of the company’s stock, valued at approximately $16,564,111.28. The disclosure for this sale can be found here. In the last 90 days, insiders have sold 220,315 shares of company stock valued at $32,107,270. Company insiders own 1.80% of the company’s stock.

A number of brokerages have issued reports on VRTX. Cowen Inc reiterated a “buy” rating on shares of Vertex Pharmaceuticals in a research note on Tuesday, August 1st. BidaskClub lowered Vertex Pharmaceuticals from a “buy” rating to a “hold” rating in a research note on Saturday, August 19th. Needham & Company LLC reiterated a “buy” rating and issued a $195.00 price target on shares of Vertex Pharmaceuticals in a research note on Friday, October 27th. BMO Capital Markets reiterated a “buy” rating on shares of Vertex Pharmaceuticals in a research note on Wednesday, September 27th. Finally, DA Davidson began coverage on Vertex Pharmaceuticals in a research note on Friday, September 29th. They issued a “buy” rating and a $200.00 price target for the company. One investment analyst has rated the stock with a sell rating, five have given a hold rating and twenty-three have given a buy rating to the company. The company currently has an average rating of “Buy” and a consensus target price of $173.15.

WARNING: This news story was first reported by Watch List News and is the property of of Watch List News. If you are reading this news story on another site, it was illegally copied and reposted in violation of US and international trademark & copyright laws. The correct version of this news story can be viewed at https://www.watchlistnews.com/fny-managed-accounts-llc-buys-shares-of-1072-vertex-pharmaceuticals-incorporated-vrtx/1728687.html.

Vertex Pharmaceuticals Company Profile

Vertex Pharmaceuticals Incorporated is engaged in discovering, developing, manufacturing and commercializing medicines for serious diseases. The Company is focused on developing and commercializing therapies for the treatment of cystic fibrosis (CF) and advancing its research and development programs in other indications.

Want to see what other hedge funds are holding VRTX? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Vertex Pharmaceuticals Incorporated (NASDAQ:VRTX).

Institutional Ownership by Quarter for Vertex Pharmaceuticals (NASDAQ:VRTX)

Receive News & Ratings for Vertex Pharmaceuticals Incorporated Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Vertex Pharmaceuticals Incorporated and related companies with Analyst Ratings Network's FREE daily email newsletter.